Eczema cream posts strong results in PhIII trial

Anacor Pharmaceuticals' ($ANAC) topical treatment for eczema easily beat placebo in two Phase III trials, sending the biotech's share soaring and setting the stage for FDA application in the first of half of 2016. More from FierceBiotech

Suggested Articles

Researchers in the U.K. have developed a technique to better predict results in liver cancer when drug-laden polymer beads are used to deliver medicines.

Researchers at Johns Hopkins have changed the structure of a new cancer drug to allow it to more easily pass the blood-brain barrier, giving it access to…

Medtronic’s world-first FDA-approved hybrid closed-loop insulin delivery system might soon face competition, as T1D Exchange has pledged to invest in the…